Events & Presentations

Date	Title
November 8, 2024	Investor Presentation
September 17, 2024	Subgroup Analysis of FOCUS Phase 3 Trial Efficacy Results
June 6, 2022	FOCUS Phase 3 Trial Results: Percutaneous Hepatic Perfusion (PHP) With Melphalan for Patients With Ocular Melanoma Liver Metastases (PHP-OCM-301/301A)
December 2, 2021	Phase 3 FOCUS Trial Results
June 7, 2021	Focus Trial Preliminary Analysis - ASCO 2021

Events and Webcasts